Spero Therapeutics Inc.

SPRO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.36

+$0.22 (+19.30%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $66.01M

Enterprise Value $17.28M

Beta 1.48

Average Volume 1.27M

Shares Outstanding (Diluted) 57.97M

Shares Change YoY 3.47%

Institutional Ownership 36.04%

Exchange NASDAQ

ISIN US84833T1034

Price Performance

Price Change 1M -6.6%

Price Change 3M -47.0%

Price Change 6M -52.7%

Price Change YTD -51.5%

Price Change 1Y -43.8%

Price Change 3Y -5.8%

Price Change 5Y -93.9%

1M CAGR (ann.) -9.5%

1Y CAGR (ann.) -43.0%

5Y CAGR (ann.) -42.8%

All-Time CAGR -22.9%

Valuation

PE Ratio 10.36

Forward PE 1.65

PEG Ratio 0.06

Forward PEG -0.11

PS Ratio 1.54

Forward PS 20.60

PB Ratio 1.49

P/FCF Ratio 3.37

P/Adj. FCF Ratio 4.23

P/OCF Ratio 3.35

EV/Sales 0.40

EV/EBIT 2.24

EV/EBITDA 2.24

EV/FCF 0.88

Earnings Yield 9.7%

FCF Yield 29.7%

Adj. FCF Yield 23.6%

Financial Health

Net Cash $50.77M

Total Debt $2.04M

Cash & Short-Term Investments $50.77M

Total Assets $52.77M

Current Ratio 6.12

Quick Ratio 6.12

Debt / Equity Ratio 0.05

Debt / EBITDA 0.27

Debt / FCF 0.10

OCF / Debt 9.58

Interest Coverage 0.00

Altman Z-Score -5.51

Piotroski F-Score 7

Margins & Profitability

Gross Profit Margin 100.0%

Operating Profit Margin 14.0%

EBITDA Margin 17.9%

Net Profit Margin 17.2%

FCF Margin 45.6%

Adj. FCF Margin 36.3%

SBC / Revenue 7.4%

SBC Impact (per share) -20.4%

Returns

Return on Assets 14.0%

Return on Equity 16.2%

Return on Invested Capital 12.6%

Return on Capital Employed 13.6%

Return on Tangible Assets 14.0%

Historical Growth (CAGR)

Revenue CAGR 3Y -6.3%

Revenue CAGR 5Y 22.9%

Revenue CAGR 10Y 29.4%

EPS CAGR 3Y -60.0%

EPS CAGR 5Y 75.8%

EPS CAGR 10Y 29.3%

FCF CAGR 3Y 17.8%

FCF CAGR 5Y 82.0%

FCF CAGR 10Y 7.2%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 1

EPS Growth Next 3Y 75.0%

Revenue Growth Next 3Y 32.1%

Earnings Date Nov 11, 2026

EPS Estimate (next Q) -$0.14

EPS Growth Est (next Q) 7.7%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number $1.37

Graham Upside 20.2%

Lynch Fair Value $2.75

Lynch Upside 141.2%

Price Target $6

Price Target Upside 426.3%

Cash Flow

Operating Cash Flow $19.58M

Free Cash Flow $19.58M

Adj. Free Cash Flow $15.59M

FCF Per Share $0.34

OCF Per Share $0.34

OCF/S Ratio 45.6%

Income Statement

Revenue $42.96M

Gross Profit $42.96M

Operating Income $6.03M

EBITDA $7.7M

Net Income $7.38M

EPS (Diluted) $0.11

Revenue / Employee $1.72M

Profit / Employee $295.32K

Employees 25